SARS-CoV-2 humoral immune responses in convalescent individuals over 12 months reveal severity-dependent antibody dynamics
Open Access
- 2 May 2025
- journal article
- research article
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-13
Abstract
Background Defining the kinetics of SARS-CoV-2 antibody responses is critical for informing the management of reinfections, vaccinations, and therapeutics of Coronavirus disease 2019 (COVID-19). Methods Using four antibody assays, we evaluated antibody titers against SARS-CoV-2 nucleocapsid (N), spike (S), and receptor binding domain (RBD) in 98 convalescent participants with varying COVID-19 disease severities (asymptomatic, mild, moderate or severe) at 1, 3, 6, and 12-months post-SARS-CoV-2-positive PCR and in 17 non-vaccinated, non-infected controls. Results Increasing acute COVID-19 disease severity correlates with higher anti-N and anti-RBD titers throughout 12 months post-infection. Anti-N and anti-RBD titers decline over time in all participants, except for increased anti-RBD titers post-vaccination, with hospitalized participants exhibiting faster decay rates. Less than 50% of participants retain anti-N titers above controls at 12 months, with non-hospitalized participants falling below controls sooner. Nearly all participants maintain anti-RBD titers above controls for 12 months, suggesting long-term protection against severe reinfections. Nonetheless, by 6 months, few participants retain >50% of their initial 1-month anti-N or anti-RBD titers. Notably, vaccine-induced anti-RBD titers are higher in non-hospitalized participants. Lastly, early convalescent titers correlate with age but not with Post-Acute Sequelae of SARS-CoV-2 infection (PASC) status or steroid use. Conclusion Hospitalized participants initially develop higher anti-SARS-CoV-2 antibody titers that decline faster relative to non-hospitalized participants. While anti-N titers fall below control levels in some participants, anti-RBD titers remain above controls over 12 months, demonstrating long-lived antibody responses known to protect against severe disease. These findings advance our understanding of COVID-19 antibody dynamics.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA K08 T26-1616-11)
- Division of Intramural Research (R01AI104870, R01AI104870, R01AI104870)
This publication has 41 references indexed in Scilit:
- Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapyMultiple Sclerosis and Related Disorders, 2022
- Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC studyEBioMedicine, 2022
- Monoclonal antibody therapies against SARS-CoV-2The Lancet Infectious Diseases, 2022
- The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort studyVaccine, 2022
- Persistence assessment of SARS-CoV-2-specific IgG antibody in recovered COVID-19 individuals and its association with clinical symptoms and disease severity: A prospective longitudinal cohort studyInternational Immunopharmacology, 2021
- Natural killer cells and unconventional T cells in COVID-19Current Opinion in Virology, 2021
- Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infectionInternational Journal of Infectious Diseases, 2021
- Antibody titers against SARS-CoV-2 decline, but do not disappear for several monthseClinicalMedicine, 2021
- Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAsClinical Microbiology and Infection, 2020
- Immune response in COVID-19: A reviewJournal of Infection and Public Health, 2020